What it sells
Our drugs engage the immune system to fight tumors
Business model breakdown
Buyer: who owns the budget?
UnverifiedProspective pharma licensing partners and investors.
Workflow: what inputs become what output?
Block a cancer immune-evasion pathway with a first-in-class, orally administered small-molecule inhibitor that does not rely on a protein target, re-awakening the immune system.
Economics: what it saves and how it charges
UnverifiedPreclinical/early drug developer; revenue model not stated, likely licensing or partnering.
Distribution: how it reaches customers
Contact via info@erisbio.com; no commercial channel yet.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.